keyword
MENU ▼
Read by QxMD icon Read
search

Beloranib

keyword
https://www.readbyqxmd.com/read/28261955/a-randomized-placebo-controlled-trial-of-beloranib-for-the-treatment-of-hypothalamic-injury-associated-obesity
#1
Ashley Shoemaker, Joseph Proietto, M Jennifer Abuzzahab, Tania Markovic, Jaret Malloy, Dennis D Kim
AIMS: Hypothalamic injury-associated obesity (HIAO) results from damage to the hypothalamus that often occurs with surgical removal/radiation therapy of tumours in the hypothalamic region, such as craniopharyngioma. There is currently no rigorously studied pharmaceutical treatment for the intractable weight gain and cardiometabolic consequences that occur in patients with HIAO. We aimed to assess efficacy, safety and tolerability of beloranib treatment for 4 to 8 weeks in patients with HIAO...
March 6, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28245771/current-drug-targets-in-obesity-pharmacotherapy-a-review
#2
Sangeeta P Bhat, Arun Sharma
Obesity, an impending global pandemic, is not being effectively controlled by current measures such as lifestyle modifications, bariatric surgery or available medications. Its toll on health and economy compels us to look for more effective measures. Fortunately, the advances in biology and molecular technology have been in our favour for delineating new pathways in the pathophysiology of obesity and have led to subsequent development of new drug targets. Development of anti-obesity drugs has often been riddled with problems in the past...
February 27, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/27998678/novel-reversible-methionine-aminopeptidase-2-metap-2-inhibitors-based-on-purine-and-related-bicyclic-templates
#3
Timo Heinrich, Hans-Peter Buchstaller, Bertram Cezanne, Felix Rohdich, Jörg Bomke, Manja Friese-Hamim, Mireille Krier, Thorsten Knöchel, Djordje Musil, Birgitta Leuthner, Frank Zenke
The natural product fumagillin 1 and derivatives like TNP-470 2 or beloranib 3 bind to methionine aminopeptidase 2 (MetAP-2) irreversibly. This enzyme is critical for protein maturation and plays a key role in angiogenesis. In this paper we describe the synthesis, MetAP-2 binding affinity and structural analysis of reversible MetAP-2 inhibitors. Optimization of enzymatic activity of screening hit 10 (IC50: 1μM) led to the most potent compound 27 (IC50: 0.038μM), with a concomitant improvement in LLE from 2...
December 8, 2016: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/27849360/robust-reductions-of-excess-weight-and-hyperphagia-by-beloranib-in-rat-models-of-genetic-and-hypothalamic-obesity
#4
Clinton T Elfers, Christian L Roth
Hypothalamic lesions or deficient melanocortin (MC) signaling via MC4 receptor (MC4r) mutations often lead to hyperphagia and severe treatment-resistant obesity. We tested the methionine aminopeptidase 2-inhibitor beloranib (ZGN-440) in 2 male rat models of obesity, one modeling hypothalamic obesity with a combined medial hypothalamic lesion (CMHL) and the other modeling a monogenic form of obesity with MC4r mutations (MC4r knockout [MC4rKO]). In CMHL rats (age 3 months), postsurgery excess weight gain was significantly inhibited (ZGN-440, 0...
January 1, 2017: Endocrinology
https://www.readbyqxmd.com/read/27277818/exploratory-literature-meta-analysis-to-characterize-the-relationship-between-early-and-longer-term-body-weight-loss-for-antiobesity-compounds
#5
Nele Plock, Leon Bax, Douglas Lee, Deborah DeManno, Gezim Lahu, Marc Pfister
The presented analysis was performed to characterize the relationship between treatment-related early (week 4) and longer term (3-6 months) weight loss to understand the potential utility of 4-week proof-of-mechanism studies in the early decision-making process during clinical development of new antiobesity compounds. A regression-based meta-analysis was performed leveraging publically available clinical outcomes data to (1) characterize the within-trial relationship between treatment-related early and longer term body weight loss and (2) identify and quantify key covariate effects on this relationship...
January 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/26686773/spiroepoxytriazoles-are-fumagillin-like-irreversible-inhibitors-of-metap2-with-potent-cellular-activity
#6
Michael Morgen, Christian Jöst, Mona Malz, Robert Janowski, Dierk Niessing, Christian D Klein, Nikolas Gunkel, Aubry K Miller
Methionine aminopeptidases (MetAPs) are responsible for the cotranslational cleavage of initiator methionines from nascent proteins. The MetAP2 subtype is up-regulated in many cancers, and selective inhibition of MetAP2 suppresses both vascularization and growth of tumors in animal models. The natural product fumagillin is a selective and potent irreversible inhibitor of MetAP2, and semisynthetic derivatives of fumagillin have shown promise in clinical studies for the treatment of cancer, and, more recently, for obesity...
April 15, 2016: ACS Chemical Biology
https://www.readbyqxmd.com/read/26648466/approaches-for-the-development-of-drugs-for-treatment-of-obesity-and-metabolic-syndrome
#7
REVIEW
Maksim L Maksimov, Andrey A Svistunov, Vadim V Tarasov, Vladimir N Chubarev, Marco Ávila-Rodriguez, George E Barreto, Olga V Dralova, Gjumrakch Aliev
Obesity and metabolic syndrome (MS) are risk factors for diabetes, cancer, some cardiovascular and musculoskeletal diseases. Pharmacotherapy should be used when the body mass index (BMI) exceeds 30 kg/m² or 27 kg/m² with comorbidity. Efficacy and safety of pharmacotherapy depend on the mechanism of action of drugs. In this context, drugs affecting the central and peripheral mediator systems such as cannabinoid receptor antagonists (Rimonabant), neuronal reuptake inhibitor of NE and 5 HT (Sibutramine), neuronal reuptake inhibitor of NE 5-HT DA (Tesofensine), agonist of 5 HT 2C receptors (Lorcaserin) have a high risk of side effects on the central nervous and cardiovascular systems when used for a long period...
2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/26346394/horizons-in-the-pharmacotherapy-of-obesity
#8
REVIEW
Jonathan R S Arch
Obesity drugs have had a chequered history. In the recent past, only the low efficacy, pancreatic lipase inhibitor orlistat was available worldwide and it was little used. The 5HT2C agonist, lorcaserin, and two combinations of old drugs have been approved in the United States but not in Europe. The diabetes drug liraglutide has been approved in both the US and Europe and seems likely to be most widely accepted. In view of regulators' caution in approving obesity drugs, some (like beloranib) may initially be progressed for niche obesity markets...
December 2015: Current Obesity Reports
https://www.readbyqxmd.com/read/26040215/current-and-emerging-medications-for-overweight-or-obesity-in-people-with-comorbidities
#9
REVIEW
K Fujioka
Recently, the recognition of obesity as a complex disease that requires chronic management has become more widespread. There has also been a movement away from a focus on body mass index alone, and toward the management of obesity-related comorbidities as well as excess weight. This article examines the current and emerging pharmacological options for weight management in people with overweight or obesity who have, or are at a high risk of, weight-related comorbidities. In the USA, the current options for pharmacological weight management are phentermine (indicated for short-term use only), orlistat, combined phentermine/topiramate extended release, lorcaserin, naltrexone/bupropion and liraglutide 3...
November 2015: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/25751824/aspergillus-angiogenesis-and-obesity-the-story-behind-beloranib
#10
REVIEW
Robert H Howland
Fumagillin, an antimicrobial compound first isolated in 1949 from the fungus Aspergillus fumigatus, four decades later was unexpectedly found to inhibit angiogenesis. Interest in developing angiogenesis inhibitor drugs as possible treatments for cancer led to the synthesis of analogs of fumagillin. Preclinical studies of various analog drugs confirmed that they inhibited angiogenesis, but they also were associated with weight loss as an adverse effect. Because adipose tissue can grow and regress throughout adulthood, is highly vascularized, and has angiogenic properties, interest in investigating anti-angiogenic agents in animal models of obesity found that fumagillin analogs caused dose-dependent reversible weight reduction and adipose tissue loss...
March 2015: Journal of Psychosocial Nursing and Mental Health Services
https://www.readbyqxmd.com/read/25732625/efficacy-and-safety-of-beloranib-for-weight-loss-in-obese-adults-a-randomized-controlled-trial
#11
RANDOMIZED CONTROLLED TRIAL
D D Kim, J Krishnarajah, S Lillioja, F de Looze, J Marjason, J Proietto, S Shakib, B G A Stuckey, J E Vath, T E Hughes
AIM: To assess the efficacy, safety and tolerability of beloranib treatment for obesity. METHODS: This phase II, double-blind, randomized study investigated the effects of beloranib suspension (0.6, 1.2 and 2.4 mg) or placebo, administered subcutaneously, for 12 weeks in 147 participants (primarily white women) with obesity. No diet or exercise advice was administered. RESULTS: At week 12, beloranib resulted in dose-dependent progressive weight loss of -5...
June 2015: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/24611021/inhibition-of-the-methionine-aminopeptidase-2-enzyme-for-the-treatment-of-obesity
#12
REVIEW
Amit A Joharapurkar, Nirav A Dhanesha, Mukul R Jain
Worldwide prevalence of obesity has nearly doubled since 1980. Obesity is the result of interactions among the environmental factors, genetic predisposition, and human behavior. Even modest weight reduction in obese patients provides beneficial health outcomes. For effective weight reduction, a drug should either increase energy expenditure or decrease energy intake without causing serious adverse effects. To overcome lack of efficacy and central nervous system related side effects, exploitation of the peripheral mechanism of anti-obesity action is needed...
2014: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
https://www.readbyqxmd.com/read/24064009/new-and-emerging-drug-molecules-against-obesity
#13
REVIEW
Melvin George, Muthukumar Rajaram, Elangovan Shanmugam
Obesity has become a growing pandemic of alarming proportions in the developed and developing countries over the last few decades. The most perturbing fact regarding obesity is the increased predisposition for coronary artery disease, congestive heart failure and sudden cardiac death. The modest efficacy of current anti-obesity agents such as orlistat and the increasing withdrawals of several anti-obesity agents such as sibutramine, rimonabant have led to huge gaps in the pharmacotherapy of obesity. Lorcaserin and Phentermine-topiramate combination (phen-top) are two drugs approved by US FDA in 2012...
January 2014: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/23512440/ascending-dose-controlled-trial-of-beloranib-a-novel-obesity-treatment-for-safety-tolerability-and-weight-loss-in-obese-women
#14
RANDOMIZED CONTROLLED TRIAL
T E Hughes, D D Kim, J Marjason, J Proietto, J P Whitehead, J E Vath
OBJECTIVE: Evaluate the safety and tolerability of beloranib, a fumagillin-class methionine aminopetidase-2 (MetAP2) inhibitor, in obese women over 4 weeks. DESIGN AND METHODS: Thirty-one obese (mean BMI 38 kg/m2) women were randomized to intravenous 0.1, 0.3, or 0.9 mg/m2 beloranib or placebo twice weekly for 4 weeks (N = 7, 6, 9, and 9). RESULTS: The most frequent AEs were headache, infusion site injury, nausea, and diarrhea. Nausea and infusion site injury occurred more with beloranib than placebo...
September 2013: Obesity
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"